

CURRICULUM VITAE

Daniel Robert Boué

Employer: Nationwide Children's Hospital
 Department of Laboratory Medicine/ ChildLab, and
 Pediatric Pathology Associates, Columbus, OH
 700 Children's Drive
 Columbus, OH 43205
 Phone: (614) 722-5450
 Fax: (614) 722-2899
 Email: Daniel.Boue@NationwideChildrens.Org

Education and Medical Training:

Undergraduate:	Carleton College Northfield, MN	B.A., Biology Cum Laude	June 1980
Graduate/Medical School:	Univ. of Minnesota Minneapolis, MN	Ph.D., Pathobiology M.D.	December 1988 June 1991
Postgraduate Training:	Internship and Residency Training (AP/ CP) Chief Resident-Elect (AP/ CP)* *Resigned for Faculty Promotion University of California, San Diego		June 1991-July 1994 July 1994-June 1995
	Pediatric Pathology Fellow (AP/CP) Clinical Instructor in Pathology Children's Hospital and the Ohio State University, Columbus, Ohio		July 1995- June 1996
	Pediatric Neuropathology Fellow Clinical Instructor in Pathology Children's Hospital and the Ohio State University, Columbus, Ohio		Jan 1996- June 1997

Appointments:

Attending Physician, UCSD Medical Center Clinical Instructor in Pathology Interim Director, Perinatal Pathology and Autopsy Service University of California, San Diego	July 1994-June 1995
--	---------------------

Staff Pathologist (AP/CP) and Director of Neuropathology	Jan 1997-present
CHTN-CCG-POG-COG/ CRI, Center for Biopathology, The Research Institute at Nationwide Children's Hospital: Review Pathologist/ Investigator COG Soft Tissue Sarcoma Group, Center for Biopathology: Pathology Review Team Neuropathology Program Director (OSU/ CCH Neuropathology and Neurology Fellows) Pregnancy Loss Referral Program, Backup Consultant Children's Hospital Columbus, OH	
Clinical Instructor of Pathology	July, 1995-June, 1998
Clinical Assistant Professor of Pathology	July, 1998-June, 2004
Clinical Associate Professor of Pathology	July, 2004-Sept, 2006
Associate Professor- Clinical Track, Pathology	Oct, 2006-present
The Ohio State University Columbus, OH	

Certification and Licensure:

Diplomate, National Board of Medical Examiners, 1992 (first attempt)
 Diplomate, ABP, Board Certified, Anatomic and Clinical Pathology, 1995 (first attempt)
 Diplomate, ABP, Board Certified, Pediatric Pathology, 1999 (first attempt)
 Medical Board of California, Full and Unrestricted License, 1993-present
 Medical Board of Ohio, Full and Unrestricted License, 1997-present

Awards / Honors:

Mortar Board, National Collegiate Senior Honor Society	1980
University of Minnesota Medical Scientist (MD/PhD) Scholar	1982-1991
G.T. Evans Scholar, Department of Laboratory Medicine and Pathology	1982-1985
	1990-1991
National Life & Health Insurance Medical Research Fund Scholar	1985-1990
National Sheard-Sanford Research Award (Amer. Soc. Clinical Pathology)	1988
J.T. Livermore Award (Hematology, MN Medical Foundation)	1988
Alpha Omega Alpha National Medical Honor Society	1990
Dr. Vernon D.E. Smith Award (MN Medical Foundation)	1990
Undergraduate Medical Student Research Award (MN Medical Found.)	1991
Marquis Who's Who in Medicine and Healthcare, since 2 nd ed. 1999.	1998-present
Marquis Who's Who in Science and Engineering, since 5 th ed. 2000.	1999-present
Marquis Who's Who in America, since 54 th ed. 2000.	1999-present
Guide to America's Top Physicians; Consumers Research Council of Am.	2002-present
Marquis Who's Who in American Education, since 6 th ed. 2004.	2003-present
Educator of the Year, Children's Hospital, Dept. of Laboratory Medicine.	2006
Guide to America's Top Pathologists (new publication)	
Consumers Research Council of America (www.consumersresearchcncl.org)	2007-present

Service Duties:

Pediatric surgical pathology, autopsy pathology, and hematopathology services.
 Evening and weekend call rotations for both AP and CP.
 Pediatric neurosurgical pathology (CNS, PNS, and Muscle/Nerve Biopsies)
 Pediatric autopsy neuropathology (CNS, PNS, and Muscle/Nerve Biopsies)
 Evening and weekend call (24/7) for Neurosurgical pathology.
 CHTN/ CCG/ COG nervous system tumor review pathologist.
 Neuropathology referral/ consultation service (surgical and autopsy).
 Neuropathology Program Director (for Nsrg, Neurol, Npath residents and fellows)
 IRSG/Soft Tissue Sarcoma review team, backup consultant.
 Pregnancy Loss Referral Program, backup consultant.
 General Clinical Lab/Blood Bank, backup consultant.

Teaching Activities: (* = past)

Pathol, Pediat, Surg, Neurol, Neurosurg, Residents, Fellows, Medical Students.
 Pathology for Neurosurgery/Neurology Grand Rounds and Neurosurgery Board review.
 Pediatric Surg. Grand Rounds (yearly updates) on PNS tumors and/or Muscle Pathology.
 OSU Medical Student year II Pathology Labs (Congenital Heart and Neuropathology)*
 OSU/CCH Neuropathology and Neurology Fellow elective rotations (1-2 mo/yr)
 Shannon Standridge, Pediatric Neurology Fellow, 7/05
 Hamza Alsayouf, Pediatric Neurology Fellow, 8/06
 Prinyarat Burusnukul, Pediatric Neurology Fellow, 4/08 and 5/08
 Mark Ferrante, Neuromuscular Fellow, 5/08
 OSU/CCH Perinatal / Placental pathology, backup consultant
 CCH Pediatric Pathology Fellows (Surgical, Autopsy, Hemato-, and Neuro-Path).
 In-service didactic presentations to clinical and dept. staff.
 Multiple lectures and presentations to pediatric pathology fellows and residents on:
 pediatric brain tumor and neuromuscular pathology, and autopsy neuropathology
 OSU pathology resident lectures in Neuromuscular pathology (2-4 yearly) beginning
 May, 2006
 OSU Brain Tumor Research Seminars, Mondays at Noon, as of 1/06*

Manuscript Review Activities:

Pediatric and Developmental Pathology, ad hoc
 Annals of Neurology, ad hoc
 Children's Hospital Medical Student year III-IV Pediatric Rotation (Neuropath subjects)

Professional Societies:

American Society of Clinical Pathologists Fellow, ASCP (1996)	1991- present
College of American Pathologists; S/P Inspector #601649 Fellow, CAP (1996)	1992- present
Society for Pediatric Pathology	1995- present

Central Ohio Society of Pathologists	1998- 2002
Children's Oncology Group	1997- present
American Assoc. of Neuropathologists	2005- present

Committees:

Children's Hospital Legislative Advocacy Network. (currently designated as CAN: Children's Action Network)	2000-present
Children's Hospital Medical Leadership Program. (One of 20 CCH medical staff accepted for two-year medical leadership training program, 9/04-6/06)	2004-2006
American Assoc. of Neuropathologists, Awards committee	2007-2008
Planning Committee and Course Co-Director, Pediatric Brain Tumors: Advances in Molecular Biology, Therapies and Outcomes Conference, Columbus Children's Research Institute, Columbus (Nationwide) Children's Hospital, COG, and OSUCCC.	Sept. 6- 8, 2007

Grants:

NIH # U10 CA 98543 (internal # 3242-YR); *active*; Title: Children's Oncology Group/ Bio-Pathology Center/ Co-Investigator; PI: Gregory Reaman, M.D., with Stephen J. Qualman, M.D; Research / Review Pathologist; 5% release/ compensated effort through 2005). 2.5% compensated effort as of 2006; Sponsor: National Childhood Cancer Foundation/ NIH/ NCI; Annual direct costs: \$914,623; 3/1/03 - 2/28/09.

NIH # UO1 CA 54021-09, Title: CHTN, Pediatric Division, Year 4/5, Collaborating Investigator/Review Pathologist, 20% release time; Sponsor: NIH/ NCI, proposal # 393700, 1997- 3/31/01.

NIH # 5U10 CA 098543-04 (internal # 3570-YR); *active*; Title: Children's Oncology Group/ Bio-pathology Center/ Specimen Banking/ Co- Principal Investigator; PI: Gregory Reaman, M.D., with Stephen J. Qualman, M.D.; 5% release time (WOC); Sponsor: National Childhood Cancer Foundation/ COG/ NIH/ NCI; \$415,553; 5/3/05 - 3/31/09.

NIH # RO1, Title: Effects of disruption of Survivin during normal mouse brain development, and development and progression of mouse brain tumors, Collaborating Investigator, 5% release time; Submitted 2003, 04, 05 (PI: Dr. Rachel Altura). Sponsor: NIH, proposal # unknown: *not funded*.

NIH # UNK, Title: The pathogenetic mechanisms of the vasculopathy in Juvenile Dermatomyositis, Collaborating Investigator, 0% release time (none requested); Submitted 9/04: *funded as a pilot study only at this time* for \$21,293 (PIs: Drs. Alexei Grom, Cincinnati Children's and Gloria Higgins, Columbus Children's). Sponsor: NIH, proposal # unknown.

Children's Hospital Research Foundation, Col. OH, Title: FUSION GENE ANALYSIS IN MEDULLOBLASTOMA. Amount: \$22,500, J.A. Kass Memorial Endowment Fund, Time period: 8/01-8/02, Involvement: Principal Investigator. Status: Approved.

Children's Hospital Research Foundation, Col. OH, Title: MARKERS OF PROLIFERATION AND AGGRESSION, AND PROGNOSIS, IN LOW AND HIGH GRADE PEDIATRIC BRAIN TUMORS. Amount: \$60,000, J.A. Kass Memorial Endowment Fund, Original time period: 8/02-8/03 (renewed yearly, currently to 12/31/07, active, Grant #251903, Involvement: Principal Investigator. Status: Approved.

Grant # 377105, Title: National Education Network for Duchenne and Becker Muscular Dystrophy, Collaborating Investigator/Co-Investigator, *15% Comp.*; Submitted 05/06; (PI: Dr. Jerry R. Mendell). Sponsor: NIH, *not funded*.

Center of Research Translation, NIAMS, NIH; grant proposal # AR055502-01, Title: Gene therapy for Duchenne Muscular Dystrophy (DMD) in a mouse DMD model, *5% release time (WOC)* as pathology consultant/ collaborator; PI: Jerry R. Mendell, submitted December, 2006; Status: resubmitted 2007.

Hunan Cancer Genome Project contract, *5% release time*, pending 2008, for QA diagnostic review of Glioblastoma Multiforme brain tumors, for investigation

Original Manuscripts:

1. LeBien TW, **Boué DR**, Kersey JH. Studies of human leukemic lymphoid progenitor cell differentiation with the phorbol ester TPA. In: Experimental Hematology Today 1982. S Baum, CD Ledney, and S Thierfelder (eds.) Springer-Verlag, NY. pp 171-8. 1982.
2. LeBien TW, **Boué DR**, Bradley JG, Kersey JH. Antibody affinity may influence antigenic modulation of the common acute lymphoblastic leukemia antigen in vitro. J of Immunology 129:2287, 1982.
3. LeBien TW, Bradley JG, **Boué DR**, Platt LJ, Michael AF, Kersey JH. B cells and kidneys: A "B + CALLA" workshop analysis. In: Leukocyte Typing; Human Leucocyte Differentiation Antigens Detected by Monoclonal Antibodies. A Bernard, L Boumsell, J Dausset, C Milstein, S Schlossman (eds.), Springer-Verlag, New York. pp 346-53. 1984.
4. Allen JI, Ferrone S, **Boué DR**, Kay N. The monoclonal antibody CJA3 down-regulates the susceptibility of human tumor cell lines to natural killer cell-mediated cytotoxicity. J of Immunology 136:2318. 1986.
5. **Boué DR**, LeBien TW. Structural characterization of the human B lymphocyte-restricted differentiation antigen CD22 - Comparison with CD21 (Complement Receptor Type 2/Epstein-Barr Virus receptor). J of Immunology 140:192. 1988.
6. **Boué DR**, LeBien TW. Expression and structure of CD22 in acute leukemia. Blood 71:1480. 1988.
7. **Boué DR**. Possible functional roles for the human B cell surface glycoproteins CD22 and CD21 (Complement Receptor Type 2/Epstein-Barr Virus receptor) during early B cell activation. Ph.D. Thesis, University of Minnesota. 1988.

8. **Boué DR**, Smith GA, Krous HF. Lingual Bronchogenic Cyst in a Child: An unusual site of presentation. *Pediatric Pathology* 14:201-5. 1994.
9. **Boué DR**, Stanley C, Baergen RN. Long umbilical cord with torsion and diffuse chorionic surface vein thrombosis: multiple associated congenital abnormalities including destructive encephalopathy. *J of Perinatology* 15 (5):429-31. 1995.
10. Baergen RN, **Boué DR**, Mannino F. Liveborn twin of an extramembranous pregnancy. *J of Perinatology* 15(6):510-3. 1995.
11. **Boué DR**, Frank J, Haghighi P, Russack V. Pulmonary artery sarcoma in endarterectomy specimens: clinicopathologic study of 6 cases. *Cardiovascular Pathobiology* 1(1):48-58. 1996.
12. Lo WD, Chen RM, **Boué DR**, Stokes BT. Effect of neutrophil depletion in acute cerebritis. *Brain Research* 802: 175-183. 1998.
13. Kim S, Kosnik E, Madden C, Moran D, Rusin J, Gordon T, **Boué D**. Lytic Skull metastases from a follicular thyroid carcinoma in a child. *Pediatric Neurosurgery* 28 (2): 84-88. 1998.
14. **Boué DR**, Parham DM, Webber B, Crist WM, Qualman SJ. Clinicopathologic study of Ectomesenchymomas from Intergroup Rhabdomyosarcoma Study Groups III and IV. *Pediatric and Developmental Pathology* 3: 290-300. 2000.
15. Coley BD, Rusin JA, **Boué DR**. Importance of hypoxic/ischemic conditions in the development of cerebral lenticulostriate vasculopathy. *Pediatric Radiology* 30: 846-855. 2000.
16. Tsao CY, Herman G, **Boué DR**, Prior TW, Lo WD, Atkin JF, Rusin J. Leigh Disease with Mitochondrial DNA A8344G Mutation: Case report and brief review. *J. Child Neurol.* Jan; 18 (1): 62-64. 2003.
17. Altura RA, Olshefski RS, Jiang Y, **Boué, DR**. Nuclear expression of Survivin in pediatric ependymomas and choroid plexus tumors correlates with morphologic tumor grade. *Brit. J. of Cancer* 89: 1743- 1749. 2003.
18. Fangusaro JR, Jiang Y, Holloway MP, Caldas H, Singh V, **Boué DR**, Hayes J, and RA Altura. Survivin, Survivin-2B, and Survivin-deltaEx3 expression in medulloblastoma: biologic markers of tumor morphology and clinical outcome. *Brit. J. of Cancer*, 1-7, 2005.
19. Mendell, JR, **Boué DR**, and Martin P. The Congenital Muscular Dystrophies: Recent Advances and Molecular Insights, *Pediatric and Dev. Pathol*, 9: 427-443, 2006.
20. Caldas H, Fangusaro JR, **Boué DR**, Holloway, MP and Altura RA. Dissecting the Role of Endothelial Survivin- Δ Ex3 in Angiogenesis. *Blood*, Oct 12, 2006 online as First Edition Paper. *Blood* 109: 1479-1489, Feb. 2007.
21. Kesserwan C, **Boué DR**, and Kahwash S. Isolated Juvenile Xanthogranuloma in the Bone Marrow: Report of a Case and Review of Literature, *Pediatric and Dev. Pathol*, 10:161-164, 2007.
22. Tsao CY, Lo WD, Rusin JA, Henwood MJ and **Boué DR**. Isolated Neurosarcoidosis presenting as Headache and Multiple Brain and Spinal Cord Lesions Mimicking Central Nervous System Metastases. *Brain & Development*, 29 (8): 514-518, 2007.
23. Mendell, JR, **Boué DR**, and Martin P. The Congenital Muscular Dystrophies: Recent Advances and Molecular Insights, in *Perspectives in Pediatric Pathology: Vol. 26, Pathology of the Central Nervous System and Muscles in Fetuses, Infants and Children*, 2007.

24. Haidet, AM, Rizo, L, Handy C, Shilling C, Umaphathi P, **Boué D**, Martin PT, Sahenk Z, Mendell JR, Kaspar BK: Long-term Enhancement of Skeletal Muscle Mass and Strength by Single Gene Administration of Myostatin Inhibitors, **2008**, Proc. Nat. Acad. Sci., *in press*
25. Granese J, **Boué DR**, Elton SW, and Ellison DW: Idiosyncratic differentiation in Medulloblastoma - a report of two exceptional cases, **2008**, Neuropathology and Applied Neurobiology, *in press*
26. Burusnukel, P, de los Reyes EC, **Boué DR**: Danon's Disease: An unusual presentation of autism, **2008**, Ped. Neurol. *in press*

Abstracts:

1. LeBien TW, **Boué DR**, Kersey JH. Studies of human leukemic lymphoid progenitor cell differentiation with the phorbol ester TPA. Midwest Autumn Immunology Conference. 1981
2. LeBien TW, **Boué DR**, Bradley JG, Kersey JH. A monoclonal antibody to the common ALL antigen which does not mediate antigenic modulation in vitro. J of Cell Biochemistry, Suppl. 6:34. 1982
3. LeBien TW, **Boué DR**, Bradley JG, Kersey JH. A monoclonal antibody to the common ALL antigen (CALLA) which does not mediate antigenic modulation in vitro. Federation Proceedings 41:328. 1982.
4. Neudorf SD, **Boué DR**, Brashem C, Bollum F, LeBien T, Kersey J. Lymphoid progenitor cells in human bone marrow and thymus. Federation Proceedings 41:270. 1982.
5. Allen J, Ferrone D, **Boué DR**, Kay N. Monoclonal antibody to human colon carcinoma that inhibits natural killer activity. American Gastroenterological Association, Chicago, IL. 1982.
6. LeBien T, Ash R, Atasoy U, **Boué DR**, Bradley JG, Zanjani E, Kersey JH. Walking the leukemic cell surface - diagnostic virtue of monoclonal antibodies. 13th International Cancer Congress, Seattle, WA. 1982.
7. **Boué DR**, LeBien TW. Structural comparison of the human B cell surface molecules CD21 (CR2/EBV Receptor) and CD22. Sixth International Congress of Immunology, Toronto, Ontario, Canada. 1993.
8. **Boué DR**, Frank J, Russack V. 1993. Primary pulmonary artery neoplasms in endarterectomy specimens. American and Canadian Academy of Pathology, New Orleans, LA. Modern Pathol 6(1):21A, #106. 1993.
9. Wall, JW, Jones KL, Kosaki, K, Baergen R, **Boué D**, Benirschke K. The Prune Belly Syndrome: evidence in support of a vascular pathogenesis. David W. Smith Annual Meeting, 1996.
10. Grafe MR, Baergen RN, **Boué DR**, Benirschke K. Long-standing intrauterine brain damage in association with chronic placental pathology. American Assoc. of Neuropathologists, Vancouver, BC, Canada. #22, 1996.
11. **Boué DR**, Parham D, Webber B, Maurer H, Qualman S. Clinicopathologic study of pediatric ectomesenchymomas from IRS III and IV. Society for Pediatric Pathology, Orlando FL. March 1997. Laboratory Medicine.

12. **Boué D**, Qualman S, Hammond S, Kahwash S, and Schauer G. Fatty acid oxidation disorders and sudden unexplained death in children. Society for Pediatric Pathology, Minneapolis, MN, Sept. 1998. *Ped and Developmental Pathology* 1(3): 250.
13. **Boué D**, Kosnik E, Rusin J, Cottingham S, Yates A, Boesel C. Recurrent and widely disseminated dysembryoplastic neuroepithelial tumor (DNT). Amer. Assoc. of Neuropathologists, Minneapolis, MN. June, 1998. *J Neuropathol Exper Neurol.*#77, 5/98.
14. Bonasso C, **Boué D**, Kosnik E. Radiation-induced secondary brain tumors: a single children's hospital experience. 5th Int'l Conf. on long-term complications of treatment of children and adolescents for cancer. Ontario, Canada. June, 1998.
15. Coley BD, Rusin JA, **Boué DR**. Mineralizing angiopathy: importance of hypoxic/ischemic conditions. 20th annual Children's Hospital Research Forum, 6/99.
16. Vokshoor A, Boesel C, Elton SW, **Boué DR**, Kosnik, EJ. Histopathology of carotid aneurysmal dilatation after surgery for Craniopharyngioma. Amer. Associa. Of Neurological Surgeons, Pediatric Section, Atlanta, Georgia, 12/99.
17. Ishag MT, **Boué DR**, Theil KS. Cytogenetic abnormalities in choroid plexus neoplasms. U.S. and Canadian Academy of Pathology, annual meeting, abs #1258, p, 213A, Atlanta, Georgia, 3/01.
18. Prior T, **Boué DR**, Herman G, Tsao CY. Leigh's Syndrome associated with a homoplasmic A8344G MERRF mutation. Amer. Soc. Medical Genetics, 2002. Submitted.
19. Seth SK, Rusin J, Martin L, Kosnik E, **Boué D**. Variable ring-enhancing components of dysembryoplastic neuroepithelial tumors. Amer. Soc. Neuroradiol., 41st Annual Meeting, 4/03, Washington D.C. Submitted Nov.02/Accepted Jan.03.
20. Seth SK, Rusin J, Kosnik E, **Boué D**. An unusual presentation of dysembryoplastic neuroepithelial tumor as a fourth ventricular mass. Amer. Soc. Neuroradiol., 41st Annual Meeting, 4/03, Washington D.C. Submitted Nov.02/Accepted Jan.03.
21. Altura RA, Olshefski RS, Jiang Y, **Boué, DR**. Expression of Survivin in normal pediatric brain and corresponding CNS tumors. Soc.of Neuro-oncology, Annual Meeting, 11/03, Keystone, CO. Submitted May,03/Accepted July,03.
22. Singh V, Fangusaro J, Altura R, **Boué D**. Topoisomerase expression in Central Primitive Neuroectodermal Tumor. Soc. For Pediatric Pathology, Annual Meeting, 3/04, Vancouver, BC, Canada. Submitted Oct.03/Accepted Nov.03. *Laboratory Investigation* (2004) 84, 275.
23. Jason Fangusaro MD, Yuying Jiang MD PhD, Vivekanand Singh MD, **Daniel Boué MD PhD**, and Rachel Altura MD. Survivin and Survivin Isoforms in Medulloblastoma Show Unique Patterns of Expression and Prognostic Value. Int'l Pediatric Neurooncology Conference, Boston, MA, June, 04, Submitted Jan. 04; Accepted.
24. Jason Fangusaro MD, Yuying Jiang MD PhD, Vivekanand Singh MD, **Daniel Boué MD PhD**, and Rachel Altura MD. Survivin and Survivin Isoforms in Medulloblastoma Show Unique Patterns of Expression and Prognostic Value. Columbus Children's Research Institute Annual Research Conference, Newark, OH, April, 04.
25. Singh V, **Boué DR**. Utility of proliferation markers MIB-1 and Topoisomerase II alpha (Topo2a) in the grading of and prediction of outcome in pediatric ependymomas. Soc. for Pediatric Pathology, Annual Meeting, 2/06, Atlanta, Georgia. Submitted Oct.05/Accepted Dec.05. *Laboratory Investigation* (2006?): in press.
26. Caldas H, Fangusaro JR, **Boué DR**, Holloway, MP and Altura RA. Role of Survivin-Delta exon3 in angiogenesis. Submitted to Experimental Biology Meeting, 2006

- (American Society of Investigative Pathology annual submeeting) 11/05; accepted for poster (1/06) in San Francisco, April 1-5, **2006**. FASEB Journal, March, 2006: 20(5): p. A1101 (abstract # 689.10).
27. Singh V, **Boué DR**. MIB-1 and Topoisomerase II alpha (Topo2a) in the grading of and prediction of outcome in pediatric ependymomas. XVIth Int'l Congress of Neuropathology, San Francisco, CA, Sept. 2006; Brain Pathology (16) suppl 1: S24 (#051).
 28. Singh V, Fangusaro J, Altura R, **Boué DR**. Topoisomerase expression in Central Primitive Neuroectodermal Tumor. XVIth Int'l Congress of Neuropathology, San Francisco, CA, Sept. 2006; Brain Pathology (16) suppl 1: S102 (#225).
 29. Oblinger JL, Beall C, **Boué DR**, Clark KR, Sahenk Z. **2008**, Prevention of mtDNA depletion in quiescent skin fibroblasts from a patient with a novel R225W mutation in the TK2 gene. Amer. Assoc. of Neurologists, 60th annual meeting, Chicago 4/18/08, *platform* presentation (Abs #486, Neurology, Volume 70, Number 11, 2008 (Suppl 1))
 30. Burusnukel, P, de los Reyes EC, Boué DR: Danon's Disease: An unusual presentation with global delayed development and autistic features with a normal cardiac evaluation. 33rd Annual Meeting, Southern Ped. Neurology Soc., **2008**, New Orleans, LA, 3/29/08, *platform* presentation
 31. Weng S, et. al. - submitted, United Mitochondrial Disease Foundation meeting

Selected Presentations/Symposia:

1. Abstract 1 at Midwest Autumn Immunology Conference, Mpls. October, 1981.
2. Abstract 3 at FASEB meeting, New Orleans. April 1982.
3. Abstract 7 at the 6th International Congress on Immunology, Toronto. July 1986
4. Manuscript 5, American Society of Clinical Pathology, Las Vegas. Fall 1988.
5. Abstract 8, American and Canadian Academy of Pathology, New Orleans. Spring 1993.
6. Abstract 10, Society for Pediatric Pathology, Orlando FL. Spring 1997. Podium Presentation.
7. Abstract 11, Society for Pediatric Pathology, Minneapolis, MN. Fall 1997. Podium Presentation.
8. Abstract 12, Amer. Assoc. of Neuropathologists, Minneapolis, MN. June, 1998. Podium Presentation.
9. Children's Hospital Grand Rounds, Current Diagnosis and Treatment of Medulloblastoma, 2000.
10. Children's Hospital Surgery Grand Rounds, Tumors of the Peripheral Nervous System, 2001.
11. Children's Hospital Pathology Grand Rounds, The Art and Science of the Muscle Biopsy, 2002.
12. Children's Hospital Grand Rounds, Myopathy, Leigh's Syndrome with MERRF mutation, and other Mitochondrial Disorders, 2003.
13. Children's Hospital Surgery Grand Rounds, The Art of the Muscle Biopsy, June, 2004 and June, 2005.
14. Moderator; SPP annual meeting, Poster Discussion, San Antonio, TX, Spring, 2005.
15. Children's Hospital, Seminars in Pathology: Introduction to the Complexities of Mitochondrial Disorders, Nov. 30, 2005.

16. Children's Hospital Medical Grand Rounds: Pompe's Disease presenting as Congenital Diaphragmatic Hernia (Glycogen Storage type IIA, Infantile Acid Maltase Deficiency) March 9, 2006.
17. Children's Hospital, Seminars in Pathology: (Pediatric) Central Primitive Neuroectodermal Tumors, an Update. Nov.1, 2006.
18. Children's Hospital, Seminars in Pathology: Clinico-pathologic features of Duchenne-Becker Muscular Dystrophy, Feb.7, 2007.
19. Children's Hospital, Seminars in Pathology: Unusual Muscle Biopsies, Dec. 5, 2007.
20. Children's Hospital, Seminars in Pathology: Findings of the Cerebrospinal fluid, June 4, 2008-pending.

RESEARCH INTERESTS:

Primary basic science and clinical research interests are in the clinical, radiologic, pathologic and molecular diagnostic and prognostic features of pediatric brain tumors, especially Medulloblastoma and Supratentorial PNET, the most common malignant pediatric brain tumors. This includes a CHRF grant (P.I.) to study the expression of various well-defined pediatric solid tumor fusion genes in these tumors, as well as a CHRF grant to study the expression of various markers of proliferation/cell cycle and aggression in pediatric brain tumors in order to correlate expression of these markers with diagnosis, treatment choice, and prognosis/outcome. Also a COG and CHTN reviewer of pediatric neoplasms, currently for all brain tumors received from outside of Children's Hospital by the CHTN for confirmation of pathologic diagnosis prior to further scientific investigation.

Additional interests include collaboration with the Neuromuscular Diagnostic and Research Laboratory of Dr. Jerry R. Mendell, collaborating on researching mouse models of Duchenne Muscular Dystrophy, Gene therapy for Duchenne Muscular Dystrophy (DMD) in a mouse DMD model.